# VISIBLE SPECTROPHOTOMETRIC METHODS FOR THE QUANTITATIVE ESTIMATION OF LOPINAVIR IN THEIR FORMULATIONS

<sup>1</sup>V.Nagalakshmi,
 <sup>2</sup>K.Sreelatha,
 <sup>3</sup>NVNB SrinivasaRao,
 <sup>4</sup>N.Gayatri Devi,
 <sup>5</sup>K.Swarnalatha,
 <sup>6</sup>M.Rama,
 <sup>7</sup>C.A.Jyothirmayee,
 <sup>8</sup>N.Madhavi,
 <sup>9</sup>K.J.Subhashishini,
 <sup>10</sup>A.Nirmala Jyothna

<sup>1,4,5,6,7,8,9,</sup> Department of chemistry, Ch.S.D.St. Theresa's college for women, Eluru-534003,
 <sup>2,10,</sup> Department of physics, Ch.S.D.St. Theresa's college for women, Eluru-534003,
 <sup>3</sup>S.Ch.V.P.M.R Government Degree College, Ganapavaram cheruvu.nagalakshmi@gmail.com

# Abstract:

Simple, accurate and reproducible UV-Visible spectrophotometric methods were established for the assay of LOP based on the substitution and condensation reactions. Condensation the LOP with Xanthydrol/H<sub>2</sub>SO<sub>4</sub> is proposed in method A. Method B includes substitution of LOP with chloranilic acid . The optical characteristics such as Beers law limits, molar absorptivity and Sandell's sensitivity for the methods (A-B) are given. Regression analysis using the method of least squares was made to evaluate the slope(b), intercept(a) and correlation coefficient (r) and standard error of estimation (Se) for each system.Determination of LOP in bulk form and in pharmaceutical formulations were also incorporated

Keywords: Estimation, Lopinavir, Condensation, Antiviral.

# I. Introduction

**Lopinavir** is a protease inhibitor. Lopinavir inhibits HIV protease, causing the enzyme incapable of processing the polyprotein precursor. This leads to the production of non infectious and immature HIV particles. The structural features, category; certain characteristics, therapeutic importance and commercially available formulations of LOP are compiled in tables 1 and 2 respectively. A very few physico – chemical methods appeared in the literature for the assay of LOP in biological fluids and pharmaceutical formulations (less). The methods so far reported include UV and visible spectrophotometric methods [1-3], chromatography[4-6], HPLC[7] in biofluids, pharmacological [8] and clinical aspects, applied radiation and isotopes, polarographic [9-11] methods. The analytically useful functional groups in LOP have not been fully exploited for designing suitable, visible spectrophotometric methods and so still offer a scope to develop more visible spectrophotometric methods with better sensitivity, selectivity, precision and accuracy. The author has made some attempts in this direction and succeeded in developing two methods i.e., [Xan - H<sub>2</sub>SO<sub>4</sub> (M<sub>1</sub>); CA (M<sub>2</sub>)]. All these methods have been extended to pharmaceutical formulations as well.

Generic Name	Chemical Name	Structure	
Lopinaxir	1(2H)-pyrimidine acetamide. N-[1S,3S,4S)-4-[(2,6- dimethyl-phenoxy) acetyl] -3- hydroxy-5-phenyl-1 (phenyl methyl) phenyl] tetra- hydro-α- (1-methyl ethyl)-2-oxo (α S).		

## **TABLE 1:** Sturctural Features Of Lopinavir

### **II. Experimental**

### 2.1 Instruments used:

An Elico, UV – Visible digital spectrophotometer with 1cm matched quartz cells were used for the spectral and absorbance measurements. An Elico LI-120 digital pH meter was used for pH measurements.

### 2.2 Preparation of standard drug solutions:

An 1 mg/ml solution was prepared by dissolving 100 mg of pure LOP in 10ml of MeOH and this stock solution was diluted step wise with distilled water to get the working standard solutions of concentration of 200g.mL<sup>-1</sup> [M<sub>1</sub>] and 250g.mL<sup>-1</sup>[M2]

#### **2.3 Proposed procedures:**

After systematic and detailed study of the various parameters involved, the following procedures [Methods **Xan-H<sub>2</sub>SO<sub>4</sub> (M1); CA (M2)**] were recommended for the assay of **LOP** in bulk samples and pharmaceutical formulations.

#### 2.4.1 For Bulk samples

# 2.4.1.1 Method - M1

Aliquots of LOP solution  $(0.5 - 3.0 \text{mL}, 200 \mu \text{g.mL}^{-1})$  were transferred into different 10mL graduated tubes and the volume of the each test tube is adjusted to 3.0mL with methanol. To each of these tubes 1.0mL of xanthydrol  $(2.32 \times 10^{-2} \text{M})$ and 1.0mL of sulphuric acid were added and the tubes were thoroughly shaken. The reaction mixture was then cooled to room temperature and total volume was adjusted to 10mL with methanol. The absorbance of each solution was measured at 650nm against a reagent blank. The amount of LOP present in the sample was computed from the calibration graph (Fig. 3).

# 2.4.1.2 Method – M2

**Into** a series of 10mL calibrated tubes containing aliquots of standard **LOP** solution (0.5 - 3.0mL,  $500\mu g.mL^{-1}$ ), 2.0mL of chloranilic acid (4.785 x  $10^{-3}M$ ) was added and kept aside for 30 min at lab temperature. The volume in each tube was made up to the mark with chloroform. The absorbance of the colored species was measured at 535nm against a reagent blank. The amount of the drug was calculated from Beer's law plot (**Fig. 4**).

#### 2.4.2 Pharmaceutical formulations:

An accurately weighed portion of tablet content equivalent to about 100mg of LOP was transferred into a 100mL volumetric flask. Added about 80mL of warm isopropyl alcohol and shaken well for about 20min. The contents were diluted with isopropyl alcohol up to the mark and mixed thoroughly. The solution was

filtered. The filtrate was evaporated to dryness. The residue was used for the preparation of formulation solutions for different methods as given under standard solutions preparations. These solutions were analyzed as under procedures described fro bulk solutions.

### **III. Results And Discussions**

### 3.1 Spectral Characteristics:

In order to ascertain the optimum wavelength of maximum absorption  $(\Box max)$  of the colored species formed in the above methods, specified amounts of LOP were taken and colors were developed separately by following the above procedures. The absorption spectra were scanned on a spectrophotometer in the wave length region of 340 to 900nm against similar reagent blank or distilled water. The reagent blank absorption spectrum of each method was also recorded against distilled water. The results were graphically represented in **Fig. 1** and **2**, The absorption curves of the colored species in each method show characteristics absorption maxima where as the blank in each method has low or no absorption in this region.

### 3.2 Method - M<sub>1</sub> [Xanthydrol]

**This** method involves the condensation of the **TAD** with Xanthydrol in the presence of acid. The effect of various parameters, such as concentration and volume of Xanthydrol, nature and strength of acid, order of addition of reagents, solvent for final dilution were studied and the optimum conditions developed and actual conditions chosen for the procedure are recorded in (**Table 2**).

### 3.3 Method - M2 [Chloranilic acid]

**This** method involves the formation of charge – transfer complex between TIA and chloranilic acid. The optimum conditions in this method were fixed based on the study of the effects of various parameters such as strength and volume of reagent, solvents used initially and subsequently in final dilution in the formation and stability of the colored species. The author performed control experiments by measuring the absorbance at 540nm of a series of solutions varying one and fixing the other parameters and the results are incorporated in (**Table 2**).

#### **3.3 Optical Characteristics:**

In order to test whether the colored species formed in the above methods, adhere to Beer's law the absorbance's at appropriate wave lengths of a set of solutions containing varying amounts of LOP and specified amounts of reagents (as given in the recommended procedures for each method) were recorded against the corresponding reagent blanks. The Beer's law plots of these systems are recorded against the corresponding reagent blanks. The Beer's law plots of these systems are recorded graphically (**Figs. 3 to 4**). Beer's law limits, molar absorptivity, Sandell's sensitivity and optimum photometric range (**Table. 3**) for LOP in each method

developed. With mentioned reagents were calculated. Least square regression analysis was carried out for getting the slope, intercept and correlation coefficient values. (**Table. 2**).

#### **3.4 Precision:**

The precision of each proposal methods was ascertained from the absorbance values obtained by actual determination of six replicates of a fixed amount of LOP in total solution. The percent relative standard deviation and percent range of error (at 0.05 and 0.01 confidence limits) were calculated for the proposed methods (**Table 2.**)

### 3.5 Accuracy:

To determine the accuracy of each proposed method, different amounts of bulk samples of LOP within the Beer's law limits were taken any analyzed by the proposed method. The results (percent error) are recorded in (**Table 2.**).

### 3.6. Interference studies:

The effect of wide range of excipients and other active ingredients usually present in the formulations for the assay of LOP in methods **M1**, **M2**, under optimum conditions were investigated. The commonly used excipients and other active ingredients usually present in formulations did not interfere even if they were present in amount than they usually exist.

LOP				
Parameter	M15	M <sub>23</sub>		
$\lambda_{\max}$ (nm)	650	540		
Beer's law limits (µg/mL)	0.4-2.4	0.5-3.0		
Detection limit (µg/mL)	1.2955	0.1012		
Molar absorptivity (1 mol <sup>-1</sup> .cm <sup>-1</sup> )	9.314 x 10 <sup>3</sup>	9.463 x $10^3$		
Sandell's sensitivity (µg.cm <sup>-2</sup> /0.001 absorbance unit)	2.231 x 10 <sup>-2</sup>	3.708 x 10 <sup>-2</sup>		
Optimum photometric range (µg/mL)	1.1-2.4	1.26-3.0		
Regression equation (Y=a+bc)				
slope (b)	0.0140	0.0150		
Standard deviation on slope (S <sub>b</sub> )	4.573 x 10 <sup>-4</sup>	1.527 x 10 <sup>-5</sup>		
Intercept (a)	9.20 x 10 <sup>-3</sup>	1.50 x 10 <sup>-4</sup>		
Standard deviation on intercept (S <sub>a</sub> )	6.067 x 10 <sup>-3</sup>	5.066 x 10 <sup>-4</sup>		
Standard error on estimation (Se)	5.785 x 10 <sup>-3</sup>	4.830 x 10 <sup>-4</sup>		
Correlation coefficient (r)	0.9985	0.9999		
Relative standard deviation (%)	2.1739	0.9370		
% Range of error (confidence limits)				
0.05 level	2.281	0.983		
0.01 level	3.578	1.542		

Table 2 Optical and regression characteristics, precision and accuracy of the proposed methods for

\* Average of six determinations considered \*\* Average of three determinations



Fig. 1: Absorption spectrum of LOP with Xan – H<sub>2</sub>SO<sub>4</sub> (M<sub>15</sub>)

#### NOVATEUR PUBLICATIONS INTERNATIONAL JOURNAL OF INNOVATIONS IN ENGINEERING RESEARCH AND TECHNOLOGY [IJIERT] ISSN: 2394-3696 Website: ijiert.org VOLUME 10, ISSUE 6, June -2023



Fig. 2 Absorption spectrum of LOP with CA (M<sub>23</sub>)



Fig.3: Beer's Law plot of LOP with

Fig. 4: Beer's Law plot of LOP with with CA (M<sub>2</sub>) Xan – H<sub>2</sub>SO<sub>4</sub> (M<sub>1</sub>)

# **IV. Conclusions**

The proposed methods exploit the various functional groups in LOP molecule. Statistical analysis of the results shows that the proposed procedures have good precision and accuracy with good sensitivity and higher  $\lambda_{max}$ . Results of the analysis of pharmaceutical formulations reveal that the proposed methods are suitable for their analysis with virtually no interference of the usual additives present in pharmaceutical formulations. The order of  $\varepsilon_{max}$  among the proposed methods is: M<sub>2</sub>>M<sub>1</sub>. Thus, the proposed methods are simple, sensitive or selective with reasonable precision and accuracy and constitute better alternatives to the reported ones in the assay of LOP in bulk form and pharmaceutical formulations.

#### Referencees

[1]. Notari, Stefania, Bocedi, Journal of chromatography, 831 (1-2), 258-266(Eng) 2006. Dickinson, Laura, Robinson, Lesley; Journal of chromatography, 829(1-2), 82-90 (Eng) 2005.

[2]. Faux, J., Venisse, N., Oliver, F.C., Bouquet., s., Chromatographia, 54(7/8),469-473 (Eng)2001.

[3]. Tuan, Nguyen Duc; Gutleben; Electrophoresis, 24(4), 662-670 (Eng)2003.

[4]. Marzolini, C.; Deguin, A.; Telenti A.; j. Chromatography, , 774 (2), 127-140 (Eng) 2002.

[5]. Usami, Yoshiko; oki, Tsuyoshi; Nakai; Chemical and Pharmaceutical Bulletin, 51(6), 715-718(Eng(2003).

[6]. Frerichs, ValeriesA; Di Frances co, Robin., Morse. Journal of chromatography, , 787(2), 393-403 (Eng)2003.

[7]. Remtsch, Katharina M.Journal of chromatography, 788(2),339-350(Eng)2003.

[8]. Turner, MecheleL,; Reed-Walker, Kedria; King,. Journal of chromatography, 784(2),331-341 (Eng)2003.

[9]. Titier, Karine, Lagrange, Fabrice, Pehoureq, Therapeutic Drug Monitoring, 24(3), 417-424 (Eng) 2002.

[10]. Volusov, Nadrew, Alexander, J.clinical Biochemistry, 35(2), 99-103 (Eng) 2002.